Gluteus Medius Latent Trigger Point and Muscle Strength in Healthy Subjects

The Relationship Between Gluteus Medius Latent Trigger Point and Muscle Strength in Healthy Subjects

This study aimed to investigate the relationship between latent MTrPs and gluteus medius muscle strength in a group of healthy adults.

Study Overview

• Status: Completed
• Conditions: Muscle Weakness; Myofascial Pain Syndrome
• Intervention / Treatment: Device: Muscle strength measurement

Detailed Description

Latent myofascial trigger points (MTrPs) do not cause spontaneous pain; however, they may lead to a limited range of motion and muscle weakness. We hypothesized that latent MTrPs might decrease gluteus medius muscle strength in healthy individuals. Forty-eight healthy men will be included in the study. Trigger point examination for the gluteus medius will be performed bilaterally. Subjects with one or more trigger points on the dominant side and those without any trigger points will be assigned to two groups. Muscle strength for gluteus medius will be assessed with a manual muscle tester using the "break test" technique on both sides. The subjects and the examiners will be blinded. For statistical analysis, the independent sample t-test was used to compare the intergroup differences.

• Study Type: Observational
• Enrollment (Actual): 48

Contacts and Locations

Study Locations

• Turkey
  • İstanbul, Turkey, 34100
    • Biruni University Faculty of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: Male

• Sampling Method: Probability Sample

Study Population

24 participants who are clinically diagnosed with unilateral latent MTrP in the dominant side gluteus medius muscle and 24 participants who don't have latent MTrP.

Description

Inclusion Criteria:

• Patient age: 18-40 years.
• Absence of musculoskeletal complaints related to the lumbar, sacroiliac, and hip area.
• Absence of bilateral latent MTrP in the gluteus medius muscle.
• Latent trigger point in the gluteus medius muscle on the dominant side with palpation.

Exclusion Criteria:

• A history of medical treatment, physical therapy, injection therapy, or surgical treatment related to the lumbar, sacroiliac, and hip area.
• History of trauma, or malignancy or being pregnant, or if the patient is in the lactation period.
• Bilateral latent MTrP in the gluteus medius muscle.
• Presence of latent MTrP on the non-dominant side.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group 1. Latent Myofascial Trigger Point Group; 24 participants who will be clinically diagnosed with unilateral latent myofascial trigger point in the dominant side gluteus medius muscle.	Device: Muscle strength measurement; The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
Group 2. Non-Latent Myofascial Trigger Point Group; 24 participants who don't have latent myofascial trigger point.	Device: Muscle strength measurement; The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gluteus medius muscle strength	In the participant's side-lying position, the practitioner will be applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants will be asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements will be repeated three times, one minute apart, on the right and left sides. The mean of the measurements will be calculated and recorded	One month

Collaborators and Investigators

• Sponsor: Kars State Hospital

Study record dates

Study Major Dates

• Study Start (Actual): November 17, 2020
• Primary Completion (Actual): January 17, 2021
• Study Completion (Actual): January 17, 2021

Study Registration Dates

• First Submitted: November 17, 2020
• First Submitted That Met QC Criteria: November 17, 2020
• First Posted (Actual): November 23, 2020

Study Record Updates

• Last Update Posted (Actual): January 29, 2021
• Last Update Submitted That Met QC Criteria: January 28, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Keywords: Trigger point; Gluteus medius muscle
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Neurologic Manifestations; Musculoskeletal Diseases; Rheumatic Diseases; Muscular Diseases; Neuromuscular Diseases; Neuromuscular Manifestations; Muscle Weakness; Fibromyalgia; Myofascial Pain Syndromes
• Other Study ID Numbers: KarsSH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No